Trial Profile

An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Treprostinil (Primary)
Indications Pulmonary fibrosis; Pulmonary hypertension
Focus Therapeutic Use
Sponsors United Therapeutics Corporation

Most Recent Events

08 Nov 2022 Status changed from completed to discontinued.
19 Oct 2022 Results assessing the long term safety and tolerability of treprostinil in patients with PHA with interstitial lung disease, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
14 Oct 2022 According to a United Therapeutics Corporation media release, long-term data from this trial will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com